Salicylic acid 18 MG/ML Topical Cream — RxCUI 416909
RxNorm drug concept · Semantic clinical drug
RxCUI 416909
Semantic clinical drug · SCD
● Current RxNorm concept 4 FDA products
4 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI416909
Official nameSalicylic acid 18 MG/ML Topical Cream
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known assalicylic acid 1.8 % Topical Cream
FDA products mapped4
Package NDCs mapped4
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Salicylic Acid Topical: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It's designed to treat acne. Salicylic acid helps by loosening and removing dead skin cells that clog pores — the buildup that leads to breakouts. The multi-step system on this lab...
- What is this salicylic acid product actually supposed to do for my skin?
- Some mild tingling, stinging, and peeling is actually expected — that's the salicylic acid doing its job by clearing away dead skin cells. But if the burning or peeling feels exces...
- My skin feels like it's burning and peeling. Is that normal?
🕸️ Concept Web — How Salicylic acid 18 MG/ML Topical Cream Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Salicylic acid 18 MG/ML Topical Cream
RxCUI 416909 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Salicylic acid
9525IN
-
Salicylic acid
-
Dose forms 4
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Salicylic acid Topical Cream
377804SCDF -
Salicylic acid Topical Product
1157604SCDG -
Topical Cream
316982DF -
Topical Product
1151122DFG
-
Salicylic acid Topical Cream
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Salicylic acid 18 MG/ML
331410SCDC
-
Salicylic acid 18 MG/ML
Showing up to 8 concepts per family — 6 of 6 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Salicylic acid 18 MG/ML
SCDC · 331410 -
Salicylic acid Topical Cream
SCDF · 377804 -
Salicylic acid Topical Product
SCDG · 1157604
📦 FDA Products & Package NDCs
4 products · 4 package NDCs
4 package NDCs map to RxCUI 416909 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 62742-4193-01 | 113.5 g in 1 JAR (62742-4193-1) | Skin Renewing Cream | Allure Labs | 2020-12-07 |
| 62742-4227-01 | 113 g in 1 JAR (62742-4227-1) | Skin Renewing Cream | Allure Labs | 2023-04-27 |
| 76354-0412-21 | 1 BOTTLE in 1 BOX (76354-412-21) / 21 g in 1 BOTTLE | Acne Fighting Putty Primer | e.l.f. Cosmetics, Inc | 2021-02-20 |
| 83509-0002-01 | 1 TUBE in 1 CARTON (83509-002-01) / 10 mL in 1 TUBE | Bubble Knock Out Acne Spot Treatment | BUBBLE BEAUTY | 2023-04-01 |
Observed labelers:
Allure Labs (2) ·
BUBBLE BEAUTY (1) ·
e.l.f. Cosmetics, Inc (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.